U.S. Markets closed

Need To Know: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insiders Have Been Selling Shares

Liliana Gabriel

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we’ll take a look at whether insiders have been buying or selling shares in Puma Biotechnology, Inc. (NASDAQ:PBYI).

What Is Insider Selling?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, such insiders must disclose their trading activities, and not trade on inside information.

We don’t think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.’

Check out our latest analysis for Puma Biotechnology

Puma Biotechnology Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by Founder Alan Auerbach for US$91k worth of shares, at about US$20.67 per share. That means that an insider was selling shares at slightly below the current price (US$27.40). While their view may have changed since they sold, this isn’t a particularly bullish sign. When an insider sells below the current price, it does tend to make us wonder about the current valuation. We note that the biggest single sale was only 0.1% of Alan Auerbach’s holding.

Over the last year, we note insiders sold 6.84k shares worth US$141k. Over the last year we saw more insider selling of Puma Biotechnology shares, than buying. The average sell price was around US$20.67. It’s not ideal to see that insiders have sold at around the current price. Since insiders sell for many reasons, we wouldn’t put too much weight on it. You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

NASDAQGS:PBYI Insider Trading February 6th 19

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Puma Biotechnology Insiders Are Selling The Stock

The last three months saw significant insider selling at Puma Biotechnology. In total, insiders sold US$141k worth of shares in that time, and we didn’t record any purchases whatsoever. Overall this makes us a bit cautious, but it’s not the be all and end all.

Does Puma Biotechnology Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it’s a good sign if insiders own a significant number of shares in the company. Puma Biotechnology insiders own 13% of the company, currently worth about US$139m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Puma Biotechnology Tell Us?

Insiders sold stock recently, but they haven’t been buying. Looking to the last twelve months, our data doesn’t show any insider buying. It is good to see high insider ownership, but the insider selling leaves us cautious. Of course, the future is what matters most. So if you are interested in Puma Biotechnology, you should check out this free report on analyst forecasts for the company.

Of course Puma Biotechnology may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.